GLP-1 alone vs dual agonist
GLP-1 drugs (e.g. Wegovy)
avg. weight loss (large semaglutide study)
Dual agonist (tirzepatide)
avg. weight loss (large study, max dose)
What GIP is
GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after eating. Like GLP-1, it was originally studied for its role in insulin secretion. More recently, researchers discovered that GIP receptors are also present in the brain, fat tissue, bone and pancreas. Switching those receptors on has significant effects on appetite and how the body handles fat.
How the dual action works
Plain English:
Dual agonists work on two hunger-related signals in the brain instead of one. The second signal (GIP) also improves how the body handles fat and insulin. And because it doesn't trigger as much nausea as GLP-1 at high doses, the two can be combined at full strength. This is why dual agonists tend to produce greater weight loss than single GLP-1 drugs.
GLP-1 component
- Reduces appetite via brain receptors
- Slows gastric emptying
- Stimulates insulin secretion
- Suppresses glucagon
GIP component (what it adds)
- Additional appetite reduction via brain GIP receptors
- Improves insulin sensitivity (not just secretion)
- Enhances fat metabolism via fat cell GIP receptors
- Helps reduce GLP-1 stomach side effects
Why GIP matters for tolerability
A key engineering insight behind tirzepatide: people tolerate GIP activation well at high doses. It does not trigger significant nausea on its own. GLP-1 activation, by contrast, can cause nausea when pushed to high doses.
Tirzepatide is intentionally designed with higher potency at the GIP receptor than at GLP-1. By leading with GIP, the molecule can switch on a lot of receptors in total. That produces significant appetite suppression and weight loss, with less nausea than the same amount of GLP-1 action alone. This tilted design is part of why tirzepatide showed greater weight loss than semaglutide in a direct head-to-head trial.
What the evidence shows
One head-to-head trial compared tirzepatide with semaglutide 2.4mg over 72 weeks in 751 adults without diabetes. Tirzepatide produced significantly greater weight loss, both in body weight and in waist measurement. That is attributed to the two signals boosting each other. NEJM 2025
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: